FeesSafety
Pluang+

RenovoRx to present Q3 2026 results and growth of RenovoCath drug-delivery device at Nov 11 forum

Market News
28 Oct 2026, 15:30 WIB
GlobeNewsWire
View Source
Bullish
RenovoRx to present Q3 2026 results and growth of RenovoCath drug-delivery device at Nov 11 forum

RenovoRx, a life sciences company, announced that its CEO and CFO will present the company's third quarter 2026 financial results and business progress at the Canaccord Genuity MedTech Forum on November 11, 2026. They will highlight the commercial growth and increased adoption of RenovoRx's FDA-cleared RenovoCath device and its Trans-Arterial Micro-Perfusion (TAMP) platform, used for targeted drug delivery in cancer treatment. The company reported $1.1 million in RenovoCath sales in 2025 and record quarterly revenue of $909,000 in Q2 2026. RenovoRx is also advancing its drug-device combination therapy in a Phase III trial, with topline data expected in late 2027.

RenovoRx's upcoming presentation at the Canaccord Genuity MedTech Forum coincides with a Health sector where 42 of 150 US stocks rose and 97 fell on Pluang. For readers following Health stocks, here is Pluang's market snapshot as of Oct 28, 2026 19:11 WIB: GSK traded at USD 48.27 with a 1-day change of -5.24% and a typical hold time of 94 days, showing 100% sell order activity; Avantor Inc. (AVTR) was at USD 16.49, down 3.74%, with an 11-day hold time; Dyne Therapeutics (DYN) stood at USD 16.42, down 3.07%, with a 6-day hold time.

More News

Fed Chair Warsh must engage Congress more or risk losing support and his reforms failing.

Fed Chair Warsh must engage Congress more or risk losing support and his reforms failing.

Federal Reserve Chair Kevin Warsh is making significant changes, including reducing market guidance to encourage more real-time price setting. However, JPMorgan Chase warns that without better engagement with Congress, Warsh risks serving only one te...

Market News
Neutral
1 hour ago
La-Z-Boy sales rise 4%, expands company-owned stores, returns $32M to shareholders in Q2 2027

La-Z-Boy sales rise 4%, expands company-owned stores, returns $32M to shareholders in Q2 2027

In Q2 fiscal 2027, La-Z-Boy reported a 4% increase in consolidated sales excluding divestitures, driven by expanding company-owned stores now 62% of its network and consolidating U.S. manufacturing to reduce tariff risks. The company returned $32 mil...

Company Fundamentals
Bullish
1 hour ago
SpaceX's upcoming share unlock may pressure stock, following mixed October price reactions.

SpaceX's upcoming share unlock may pressure stock, following mixed October price reactions.

SpaceX went public with less than 5% of its shares available for trading, limiting initial selling pressure but raising concerns about future share unlocks. In October, several unlock events increased the public float, causing mixed stock reactions i...

Market News
Bearish
2 hours ago
e.l.f. Beauty outpaces On with faster growth despite On's premium brand strength and lower valuation.

e.l.f. Beauty outpaces On with faster growth despite On's premium brand strength and lower valuation.

e.l.f. Beauty and On are both strong consumer brands, with e.l.f. focusing on affordable vegan cosmetics and On on premium athletic footwear. e.l.f. Beauty grew revenue by about 40% to $1.9 billion and posted $87 million net income, leveraging major ...

Market News
Bullish
2 hours ago
Anthropic plans IPO to fund AI-driven bioscience, with potential future ties to Ginkgo Bioworks' lab automation.

Anthropic plans IPO to fund AI-driven bioscience, with potential future ties to Ginkgo Bioworks' lab automation.

Anthropic is set to go public on November 19, raising tens of billions to boost its AI capabilities in bioscience, focusing on lab automation and robotics. Ginkgo Bioworks, a leader in automated biotech labs, collaborates with OpenAI but has no curre...

Market News
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App